Summary:
- Converge Bio, an AI-powered drug discovery startup, has raised $25 million in funding from Bessemer Venture Partners and executives from companies like Meta, OpenAI, and Wiz.
- Converge Bio uses artificial intelligence and machine learning to accelerate the drug discovery process, which traditionally takes years and costs millions of dollars.
- The company's technology aims to identify potential drug candidates more efficiently, potentially leading to new treatments for various diseases.